



**GlycoMimetics, Inc.**

Innovation Today, Healing Tomorrow.

## **GlycoMimetics to Present at Upcoming Healthcare Investor Conferences**

November 9, 2017

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 9, 2017-- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows:

### **STIFEL 2017 HEALTHCARE CONFERENCE**

*When:* November 14, 2017 at 8:00 a.m. ET

*Where:* New York, NY, USA

### **JEFFERIES 2017 LONDON HEALTHCARE CONFERENCE**

*When:* November 16, 2017 at 3:20 p.m. GMT

*Where:* London, UK

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at [www.glycomimetics.com](http://www.glycomimetics.com).

### **About GlycoMimetics, Inc.**

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial for the treatment of multiple myeloma. The U.S. Food & Drug Administration recently granted GMI-1271 Breakthrough Therapy designation for the treatment of adult acute myeloid leukemia (AML) patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, Maryland, in the BioHealth Capital Region. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171109005461/en/>

Source: GlycoMimetics

### **GlycoMimetics**

#### **Investors:**

Shari Annes, 650-888-0902

[sannes@annesassociates.com](mailto:sannes@annesassociates.com)

or

#### **Media:**

Jamie Lacey-Moreira, 410-299-3310

[jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)